Maria Moustaki
Overview
Explore the profile of Maria Moustaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moustaki M, Tzetis M, Mitrakos A, Mprantzos T, Loukou I
Pediatr Pulmonol
. 2025 Jan;
60(1):e27498.
PMID: 39876081
No abstract available.
2.
Skevofilax E, Moustaki M, Loukou I, Douros K
Paediatr Respir Rev
. 2024 Feb;
51:56-65.
PMID: 38395639
One hurdle in the management of CF, a disease characterized by progressive endobronchial infection, is the presence of hypersensitivity reactions to antimicrobials due to prolonged and repetitive treatment courses. The...
3.
Loukou I, Moustaki M, Douros K
Children (Basel)
. 2024 Jan;
11(1).
PMID: 38255406
Newborn screening (NBS) has been available for the diagnosis of cystic fibrosis (CF) over the last decades. Through the implementation of NBS, a new designation emerged, that of CF related...
4.
Loukou I, Moustaki M, Douros K
Acta Paediatr
. 2023 Aug;
112(10):2039-2044.
PMID: 37602754
Aim: We aimed to familiarise clinicians with the terms cystic fibrosis transmembrane conductance regulator related metabolic syndrome (CRMS) and cystic fibrosis screen positive inconclusive diagnosis (CFSPID). We also sought to...
5.
Papachristou E, Katsagoni C, Roussou X, Tokou I, Moustaki M, Petrocheilou A, et al.
Nutrition
. 2023 Jun;
114:112091.
PMID: 37356169
Objective: Nutritional status and growth is well associated with disease outcomes and lung function in patients with cystic fibrosis (CF). Current dietary guidelines for the management of CF suggest a...
6.
Kapouni N, Moustaki M, Douros K, Loukou I
Children (Basel)
. 2023 Mar;
10(3).
PMID: 36980112
Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) is a new CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator treatment, used over the last few years, which has shown an improvement in different clinical outcomes in patients...
7.
Ioannou P, Astrinaki E, Vitsaxaki E, Bolikas E, Christofaki D, Salvaraki A, et al.
Antibiotics (Basel)
. 2022 Sep;
11(9).
PMID: 36140037
Background: Both healthcare-associated infections (HAIs) and antimicrobial resistance are associated with an increased length of stay and hospital costs, while they have also been linked to high morbidity and mortality...
8.
Kanavaki A, Kanavaki I, Zoumpoulis P, Moustaki M, Douros K, Loukou I
Curr Drug Saf
. 2022 May;
18(1):93-96.
PMID: 35570532
Background: Lumacaftor/Ivacaftor (LUM/IVA) is an approved combination therapy for cystic fibrosis (CF) patients homozygous for F508del. Objective: This study aimed to detect changes in liver stiffness measurement (LSM) in patients...
9.
Moustaki M, Loukou I, Tsabouri S, Douros K
Expert Rev Clin Immunol
. 2022 May;
18(6):581-590.
PMID: 35502686
Introduction: The links between allergen exposure and sensitization are complex and depend not only on the type of allergen but on various genetic and environmental factors. Areas Covered: This review...
10.
Loukou I, Moustaki M, Deligianni A, Sardeli O, Douros K
Children (Basel)
. 2021 Oct;
8(10).
PMID: 34682122
Spirometry is considered the gold standard method for monitoring lung function of patients with cystic fibrosis (CF) but it requires patients' cooperation and therefore it is not useful for the...